Related Experiment Videos

Lactate dehydrogenase (LDH)-linked immunoglobulin in a patient with Graves' disease treated with methimazole

R Gemma1, Y Suzuki, I Tanaka

  • 1Second Department of Internal Medicine, Hamamatsu University School of Medicine, Japan.

Insights

This case study identifies a potential autoantibody to lactate dehydrogenase (LDH) in a patient with Graves' disease treated with methimazole. The antibody may contribute to drug-induced liver injury and persistent high LDH levels.

Area of Science:

  • Endocrinology
  • Hepatology
  • Immunology

Background:

  • Graves' disease is an autoimmune disorder often treated with methimazole.
  • Methimazole can rarely cause drug-induced liver injury.
  • Autoimmune conditions can lead to complex immune responses.

Observation:

  • A 26-year-old woman on methimazole for Graves' disease developed elevated liver enzymes and lactate dehydrogenase (LDH).
  • While liver enzymes normalized, LDH remained high with abnormal isoenzyme patterns.
  • Immunoglobulin G (IgG) was found to be linked to LDH.

Findings:

  • The study suggests the presence of an autoantibody to LDH, characterized by IgG binding.
  • This autoantibody is hypothesized to be a result of the interplay between autoimmunity, methimazole treatment, and hepatic disorder.
  • The findings indicate a potential mechanism for persistent high LDH levels in this patient.

Implications:

  • This case highlights a potential immunologic complication of methimazole therapy in Graves' disease.
  • The identification of an LDH autoantibody may improve understanding of drug-induced liver injury.
  • Further research is warranted to confirm the role of LDH autoantibodies in hepatic disorders.

Related Concept Videos